Dexcom adds Ascensia’s glucose meter to CGM bundle

dexcom g5 system including cell phone and app
While data from the Dexcom G5 CGM system is used to inform treatment decisions, the system must be calibrated regularly. (Dexcom)

Dexcom and Ascensia Diabetes Care have struck a deal to provide the latter’s blood glucose meter as part of the former’s continuous glucose monitoring system for patients covered by Medicare.

The bundle, which comprises Ascensia’s Contour Next One blood glucose monitoring system and Dexcom’s G5 CGM system, is now available for patients under Medicare who are eligible for therapeutic glucose monitoring, according to a statement.

While glucose meters require a fingerprick to measure blood glucose, CGMs measure glucose levels in the interstitial fluid through a sensor inserted just under the skin. The Dexcom G5 system transmits glucose data to a smartphone or smartwatch every five minutes, where patients may view their glucose data trends.


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

Patients using the G5 system must calibrate it regularly to ensure the CGM sensor reading is “on track,” Ascensia said in the statement. Patients will use the Contour Next One system to calibrate the G5 system.

RELATED: Continuous glucose monitors get one step closer to Medicare coverage

While several CGMs are available on the market, including systems from Medtronic and Abbott, Dexcom’s G5 is the only one that is FDA-approved as a therapeutic device. The other systems are approved as adjunctive devices; the information they provide must be used alongside data from other devices, such as blood glucose monitors.

In March, the Centers for Medicare & Medicaid Services released coverage criteria for therapeutic CGMs. To be eligible for a therapeutic CGM, patients must have diabetes, use a home blood glucose monitor to test their glucose levels frequently, be treated with an insulin pump or multiple daily injections of insulin, and need to frequently adjust their insulin therapy based on data from a therapeutic CGM.

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.